Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AgenusFRA:AJ8 -3.94%48 10-Year ROIIC % is 20.51 as of Dec. 2025. GuruFocus rates FRA:AJ8 with a GF Score™ of 48/100 and a GF Value™ of €3.22 (Significantly Overvalued). The stock has 12 warning signs investors should review. Among 1,101 Biotechnology companies, Agenus ranks better than 74.93% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Agenus's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was 20.51%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Agenus's 10-Year ROIIC % or its related term are showing as below:
FRA:AJ8's 10-Year ROIIC % is ranked better than 74.93% of 1101
companies
in the Biotechnology industry
Industry Median: -19.76
vs FRA:AJ8: 20.51
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Agenus 10-Year ROIIC % Related Terms
Agenus 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Agenus's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AJ8 vs FULC, IRD, TTRX: 10-Year ROIIC % Comparison
For the Biotechnology subindustry, Agenus's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agenus 10-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agenus's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Agenus's 10-Year ROIIC % falls into.
Agenus's 10-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -17.555 (Dec. 2025) - -64.0027038 (Dec. 2015) )
/
( 263.67 (Dec. 2025) - 63.388 (Dec. 2015) )
=
46.4477038
/
200.282
=
23.19%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Agenus (FRA:AJ8) has a 10-Year ROIIC % of 20.51 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Agenus and its competitors. According to the industry distribution chart, Agenus ranks #276 out of 1101 companies in the Biotechnology industry, placing it in the top 25.1%.
Is Agenus' 10-Year ROIIC % too high?
Agenus' current 10-Year ROIIC % is 20.51. Based on the distribution chart, Agenus ranks #276 out of 1101 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Agenus has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Agenus' 10-Year ROIIC % compare to FULC and IRD?
According to the Biotechnology industry distribution chart, Agenus ranks #276 out of 1101 companies for 10-Year ROIIC %. This puts Agenus in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Biotechnology company?
A good 10-Year ROIIC % depends on the Biotechnology industry context. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Agenus and its competitors. Agenus's current 10-Year ROIIC % is 20.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agenus stock overvalued right now?
Based on GuruFocus' analysis, Agenus (FRA:AJ8) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.22, compared to a current price of €6.10 — trading 89.4% above its estimated fair value. The current 10-Year ROIIC % is 20.51. Agenus' overall GF Score™ is 48/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Agenus (FRA:AJ8), the current 10-Year ROIIC % is 20.51 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agenus (FRA:AJ8) Overvalued in 2026?
Based on GuruFocus' analysis, Agenus stock appears to be overvalued.
The current stock price of €6.10 is trading 89.4% above its estimated GF Value™ of €3.22.
GuruFocus considers Agenus to be Significantly Overvalued.
Key valuation signals for FRA:AJ8:
10-Year ROIIC %: 20.51
GF Value™: €3.22 vs. price of €6.10 (89.4% above fair value)
No single metric tells the full story. See the FRA:AJ8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
48GF Score
Get the complete analysis for FRA:AJ8
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AJ8 has been successfully added to your 
